Head-to-head · The Match Score
CoreAge Rx vs Nolu
Both scored on the same six-factor Match Score. CoreAge Rx wins this matchup with a 91 to 73 edge.
CoreAge Rx
#1 · Grade A−
Anyone who wants transparent flat pricing, fast nationwide access, and no teaser-rate bait-and-switch.
Visit CoreAge RxNolu
#76 · Grade C
Patients who want one all-in per-order price with no separate membership fee, and who will work out the true annualized cost of 4-week billing themselves.
Visit NoluFactor by factor
The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.
Price, coverage & formulary
| Detail | CoreAge Rx | Nolu |
|---|---|---|
| Semaglutide | $149/mo | $249 per 4 weeks |
| Tirzepatide | $349/mo | $339 per 4 weeks |
| Coverage | All 50 states | All 50 states plus Washington, D.C. |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injectable only | Yes |
| Match Score | 91 · A− | 73 · C |
CoreAge Rx is our #1-ranked provider overall, and it takes this matchup too — a 91 Match Score to Nolu's 73. The best all-around match: nationwide access, both molecules at one flat, no-surprise price, and an easy exit.
Nolu is still a fair pick if its strengths line up with yours — best for: Patients who want one all-in per-order price with no separate membership fee, and who will work out the true annualized cost of 4-week billing themselves.
Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.
More head-to-heads
- CoreAge Rx vs Strut Health
- CoreAge Rx vs HealthRX
- CoreAge Rx vs ShedRx
- CoreAge Rx vs Ondra Health
- CoreAge Rx vs Enhance MD
- CoreAge Rx vs Eden
Or browse alternatives to CoreAge Rx and all comparisons.
Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.